AGILE: Long-term outcomes of ivonib versus placebo in newly diagnosed acute myeloid leukemia with IDH1 mutations

According to the Phase III AGILE study (NCT03173248), Ivosidenib (Ivosidenib) has shown important clinical value in the acute myeloid leukemia (AML) treatment. In 2022, the U.S. Food and Drug Administration (FDA) approved ivonib in combination with azacitidine for newly diagnosed AML patients with IDH1 mutations, especially for those patients who are not suitable for standard intensive chemotherapy. Subsequently, the European Commission also approved this combination for use in similar patient groups in 2023, providing a new standardized regimen for the treatment of IDH1-mutated AML worldwide. The AGILE Research Center has announced the preliminary findings of the study earlier, and subsequent post-hoc analysis further evaluated the long-term efficacy and safety of the combination regimen, providing more reliable data support for clinical decision-making.

In this post hoc analysis, a total of 148 patients with newly diagnosed IDH1-mutant AML were randomly assigned to two groups: ivosidenib + azacitidine group (Ivosidenib 500 mg once daily, n = 73) and placebo + azacitidine group (n = 75). Both groups of patients received 75 mg/m² azacitidine for 7 days, with a 28-day treatment cycle. The end points of the post hoc analysis included overall survival (OS), hematological response, and transfusion dependence. The median follow-up time was 28.6 months, which provided a solid basis for long-term efficacy evaluation.

The analysis results showed that compared with the placebo+azacitidine group, the median overall survival of patients in the ivonib + azacitidine group was significantly longer, 29.3 months and 7.9 months respectively (HR, 0.42; 95% CI, 0.27-0.65; p<0.0001), showing that this combination regimen has a clear advantage in prolonging survival. In addition, hematological recovery was faster and more sustained, and the proportion of patients who were independent of blood transfusions also increased significantly, 53.8% vs. 17.1% (p=0.0004). This result suggests that the combined regimen not only prolonged the survival of patients, but also improved the quality of life and reduced the impact of blood transfusion dependence on patients' daily lives.

Among the patients (n=33) with evaluable minimal residual disease (MRD) in the ivonib + azacitidine group, approximately 30.3% of patients achieved MRD-negative status on day 14 of cycle 1 (D1 C14), which means that the tumor burden of some patients has been significantly controlled early. Further analysis found that patients with different degrees of baseline mutation reduction had differences in overall survival, and patients with MRD less than 1% had a better prognosis (p=0.03), indicating that MRD status can be used as an important indicator for efficacy prediction and provide a reference for individualized management.

In terms of safety, the combination of ivonib + azacitidine is well tolerated in patients with IDH1-mutated AML who are not eligible for intensive chemotherapy. Common adverse reactions mainly focused on controllable hematological and non-hematological events, and there were no unmanageable severe toxicities. This provides clinicians with a feasible option when treating high-risk or frail patients, ensuring treatment effectiveness while minimizing treatment burden.

In general, ivonib combined with azacitidine not only significantly prolonged the survival of patients with newly diagnosedIDH1-mutated AML, but also improved the hematological recovery speed and blood transfusion independence rate, while demonstrating the potential of early tumor burden control in MRD evaluation. The good tolerability and sustained clinical benefits of this combination make it a standardized targeted therapy for patients who are not suitable for intensive chemotherapy, providing a new practical reference for global AML treatment and laying the foundation for future IDH1 mutation-related research and personalized treatment strategies.

Reference: https://aml-hub.com/medical-information/agile-long-term-results-of-ivosidenib-vs-placebo-in-idh1-mutated-newly-diagnosed-aml